Treatment satisfaction and effectiveness of Lurasidone on quality of life and functioning in adult patients with schizophrenia in the real-world Italian clinical practice: a prospective 3-month observational study

• Published in: Annals of general psychiatry Vol. 23; no. 1; pp. 43 - 12
• Main Authors: De Filippis, Sergio, Vita, Antonio, Cuomo, Alessandro, Amici, Emanuela, Giovanetti, Valeria, Lombardozzi, Ginevra, Pardossi, Simone, Altieri, Luca, Cicale, Andrea, Dosoli, Marisa, Galluzzo, Alessandro, Invernizzi, Elena, Rodigari, Paola, Mascagni, Patrizia, Santini, Claudia, Falsetto, Nathalie, Manes, Marta Antonia, Micillo, Marco, Fagiolini, Andrea
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 05-11-2024; BioMed Central; BMC
• Subjects: Adults; Care and treatment; Health aspects; Indoor air quality; Lurasidone; Medical research; Medicine, Experimental; Patient compliance; Patient satisfaction; Patient’s satisfaction; Quality of life; Real-world; Schizophrenia; Second-generation antipsychotics (SGAs)
• ISSN: 1744-859X; 1744-859X
• DOI: 10.1186/s12991-024-00531-z

Background Although second-generation antipsychotics (SGAs) have proven to be effective therapeutic options for patients with schizophrenia, there is a notable lack of evidence on patients' subjective perspectives regarding their well-being, quality of life, and satisfaction with these medications. This study aimed to evaluate the treatment satisfaction and effectiveness of lurasidone on quality of life and functioning in adult patients with schizophrenia in real-world Italian clinical practice. Methods This was a multicentre, national, non-interventional, single-arm, 3-month prospective study. Patients who were naive to lurasidone treatment and whose treating physician had decided to start them on this medication were enrolled and evaluated over a 3-month period. Eligible patients were adults ([greater than or equal to] 18 years of age) with a primary diagnosis of schizophrenia who were being treated with lurasidone (for the first time [i.e., they were lurasidone naive]) as part of routine clinical practice. Efficacy endpoints were changes in patient/caregiver treatment satisfaction (seven-point Likert scale from the Treatment Satisfaction Questionnaire for Medication), patient quality of life and functioning (QLS), investigator-rated global assessment of functioning (CGI-S, IAQ) after 6 weeks and 3 months of lurasidone, and number of relapses and hospitalizations. Results Sixty-one patients were enrolled and 59 completed the study. The median dosage of lurasidone at baseline was 37.00 mg/day. The median duration of titration was 86.0 days (Min 28; Max 115 days); the median number of dosage changes was 1.0. At the end of 3-month observation period, the median dose of lurasidone was 74.00 mg/day. QoL and Functioning Score showed a trend of improvement over time, reaching a mean change from baseline of 9.8 at the end of the study. According to the CGI-S, the percentage of patients who were "markedly or severely ill" showed a continuous decrease from baseline to 3 months, from 62.29% to 8.20%. Patient satisfaction increased over time, with 80.32% of patients reporting that they were somewhat, fairly, or very satisfied (including 63.93% who were completely or very satisfied) at the end of the study. No relapses/hospitalizations for psychiatric reasons were reported. Lurasidone was well tolerated with no safety concerns or discontinuations due to AEs. Conclusions Lurasidone represents a valid option for the treatment of schizophrenia and positively affects subjective well-being, quality of life and satisfaction. Trial registration NCT06527885 retrospectively registered (01/08/2024). Keywords: Schizophrenia, Lurasidone, Second-generation antipsychotics (SGAs), Quality of life, Patient's satisfaction, Real-world, Observational, Prospective